Free circulating mRNA in plasma from breast cancer patients and clinical outcome

Garcı́a, Vanesa; García, José M.; Peña, Cristina; Silva, Javier; Domínguez, Gemma; Lorenzo, Yolanda; Díaz, Raquel; Espinosa, Patricia; Sola, Javier García de; Cantos, Blanca; Bonilla, Félix

doi:10.1016/j.canlet.2008.01.008

Cited by 67 publications

(53 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Any staining of ARG 2 in blood cells were considered false positive as we did not observe any ARG2 mRNA, and also support the recent study showing absence of ARG2 in blood (Yang et al, 2013). Although we observed OAT mRNA expression in blood with no detectable difference in OAT protein or mRNA expression, which might be circulating cell free mRNA (Garcia et al, 2008). We established the presence of both the isoforms of ARG in human head and neck squamous cell carcinoma tissues.…”

Section: Discussionsupporting

confidence: 89%

Modulation of L-Arginine-Arginase Metabolic Pathway Enzymes: Immunocytochemistry and mRNA Expression in Peripheral Blood and Tissue Levels in Head and Neck Squamous Cell Carcinomas in North East India

Srivastava

Ghosh²

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Arginine may play important roles in tumor progression by providing ornithine for polyamine biosynthesis, required for cell growth. The aim of this work was to determine the expression of arginine metabolic pathway enzymes in head and neck squamous cell carcinoma (HNSCC) in northeast India. Materials and Methods: The expressions of arginase isoforms (ARG1 and ARG2), ornithine aminotransferase (OAT) and ornithine decarboxylase (ODC) were examined in fifty paired HNSCC and adjacent non-tumor tissues by immunohistochemistry. Immunocytochemistry, semiquantitative reverse transcription sq-PCR and quantitative real-time qPCR were used to assess protein and mRNA expressions in peripheral blood of fifty HNSCC patients and hundred controls. Results: ARG1 and ODC protein and mRNA were strongly expressed in peripheral blood from HNSCC patients. No ARG2 expression was observed. In vivo, expression of ARG1, ARG2 and ODC was significantly higher in tumor than in non-tumor tissues. Most tumors expressed low levels of OAT, with no difference in tissues or blood, compared to controls. The absolute extent of maximal ARG1 upregulation with qPCR showed 6.23 fold increase in HNSCC. Conclusions: These findings strongly suggest that in HNSCCs, the ARG1 pathway is stimulated leading to the formation of polyamines as indicated by higher ODC expression, which promote tumor growth.

show abstract

Section: Discussionsupporting

confidence: 89%

Modulation of L-Arginine-Arginase Metabolic Pathway Enzymes: Immunocytochemistry and mRNA Expression in Peripheral Blood and Tissue Levels in Head and Neck Squamous Cell Carcinomas in North East India

Srivastava

Ghosh²

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Similarly the presence of exRNA is well documented in sera/plasma from patients presenting with breast [62][63][64] and colon cancers [65,66].…”

Section: Circulating Nucleic Acids and Cancermentioning

confidence: 99%

“…In breast cancer exRNAs have been documented by a number of research groups [63,[96][97][98]. We present the most documented studies on cell-free exRNAs and CTC associated RNAs.…”

Section: Extracellular Rnas and Ctcs Associated Rnas In Breast Cancermentioning

confidence: 99%

“…In breast cancers, cyclin D1 is over-expressed by 30-50% of tumors [140] and is documented as being predictive of poor clinical outcome [141]. García et al [63] investigated whether plasma mRNA from breast cancer patients is related to disease-free survival and overall survival. Presence of cyclin D1 plasma mRNA was significantly associated with non-responsive patients following treatment after relapse.…”

Section: Cyclin D1mentioning

confidence: 99%

See 1 more Smart Citation

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Friel

Corcoran

Crown

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Early detection of cancer is vital to improved overall survival rates. At present, evidence is accumulating for the clinical value of detecting occult tumor cells in peripheral blood, plasma, and serum specimens from cancer patients. Both molecular and cellular approaches, which differ in sensitivity and specificity, have been used for such means. Circulating tumor cells and extracellular nucleic acids have been detected within blood, plasma, and sera of cancer patients. As the presence of malignant tumors are clinically determined and/or confirmed upon biopsy procurement-which in itself may have detrimental effects in terms of stimulating cancer progression/metastases-minimally invasive methods would be highly advantageous to the diagnosis and prognosis of breast cancer and the subsequent tailoring of targeted treatments for individuals, if reliable panels of biomarkers suitable for such an approach exist. Herein, we review the current advances made in the detection of such circulating tumor cells and nucleic acids, with particular emphasis on extracellular nucleic acids, specifically extracellular mRNAs and discuss their clinical relevance.

show abstract

“…Further categorisation defines four molecular subtypes [Refs. 33,34]: luminal A which accounts for ∼50-60% of cases, luminal B accounting for 10-20%, HER 2 represents a further 15-20% and between 10 and 20% of cases are classified as a basal subtype [7,8].The Nottingham Prognostic Index (NPI) provides further prognostic information based on tumour size, lymph-node (LN) stage and tumour grading [9]. The NPI index categorises patients into 6 groups ranging from the very poor prognostic group (NPI > 6.4) to the excellent prognostic group (NPI < 2.4) [10,11].…”

mentioning

confidence: 99%

Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease

Inns

James

2015

The Breast

View full text Add to dashboard Cite

Inns, Joseph and James, Victoria (2015) Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease. The Breast, 24 (4). pp. 364-369. ISSN 1532-3080 Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/36999/1/YBRST_2141_edit_report.pdf Copyright and reuse:The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions. This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see: http://eprints.nottingham.ac.uk/end_user_agreement.pdf A note on versions:The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.For more information, please contact eprints@nottingham.ac.uk IntroductionBreast cancer is the second most common malignancy diagnosed worldwide, accounting for approximately 23% of all cancer diagnoses per year and 465,000 cancer-related deaths [1]. These cases will include early stage disease, local recurrence or metastasis in patients previously treated with a curative intent, and advanced stage disease, characterised by the significant spread of the cancer within the breast or systemically [1,2]. The metastatic cascade initiates with localised invasion of surrounding tissue, followed by systemic spread via the blood and lymphatic system and finally dissemination of tumour cells to other organs [3]. At the point of diagnosis up to 5% of patients present with metastatic disease and of those patients who show no lymph-node involvement at diagnosis, approximately 30% will develop metastases [4,5]. This subset of individuals who potentially have metastasis of early disease (MED) represent an at risk group, who may benefit from additional monitoring and augmented treatment strategies. We currently need markers to distinguish these patients from those who do not go on to develop disease recurrence. Clinical staging and molecular classificationClinical staging is essential for establishing surgical approaches and treatment regimes. The current TNM system assess primary tumour size and extent of invasion (T), the absence or presence of palpable axillary lymph nodes and indications of local invasion (N), and evidence of distant metastasis (M) [6]. The TNM system is further supplemented by the allocation of stages I-V depending on size and metastatic spread [6]. Molecular factors are also employed to assist prognosis and direct treatment strategies. Breast cancers are categorised based on the expression of oestrogen and progesterone receptors (ER and PR) and the receptor tyrosine kinase erbB-2 (ERBB2 or HER2). Further categorisation defines four molecular subtypes [Refs. 33,34]: luminal A whi...

show abstract

Free circulating mRNA in plasma from breast cancer patients and clinical outcome

Cited by 67 publications

References 22 publications

Modulation of L-Arginine-Arginase Metabolic Pathway Enzymes: Immunocytochemistry and mRNA Expression in Peripheral Blood and Tissue Levels in Head and Neck Squamous Cell Carcinomas in North East India

Modulation of L-Arginine-Arginase Metabolic Pathway Enzymes: Immunocytochemistry and mRNA Expression in Peripheral Blood and Tissue Levels in Head and Neck Squamous Cell Carcinomas in North East India

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease

Contact Info

Product

Resources

About